MLL1 Inhibitor Compounds for Selective Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective inhibitors of MLL1, a promising therapeutic target for MLL-r AML, ALL, and other cancers, as existing treatments are inadequate.
Innovation Solution
Development of novel compounds of Formula (I) and their enantiomers or pharmaceutically acceptable salts that inhibit MLL1, which can be used in pharmaceutical compositions to treat or prevent diseases mediated by MLL1, including combinations with other therapeutically active agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for MLL1-related cancers, then treatment coverage is provided, but therapeutic effectiveness is inadequate due to lack of selective MLL1 inhibition
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of the compound structure (Formula I) to optimize binding affinity and selectivity for MLL1. By varying substituents R1-R7, W, and other parameters in the molecular structure, the invention achieves compounds with enhanced therapeutic effectiveness specifically targeting MLL1 while maintaining structural feasibility for drug development.
Solution Approach 2:
The patent uses the compound of Formula I as an intermediary substance that mediates between the therapeutic goal (inhibiting MLL1) and the biological target (MLL1 enzyme). This intermediary compound selectively binds to MLL1, blocking its enzymatic activity and thereby treating MLL1-related cancers without requiring direct genetic manipulation or other complex interventions.
2Reliability
If novel compounds of Formula (I) are developed to selectively inhibit MLL1, then therapeutic effectiveness is improved, but development complexity and time increase
Solution Approach 1:
The patent applies segmentation by dividing the complex drug development process into manageable components: (1) identifying the core molecular scaffold, (2) systematically varying specific substituents (R1-R7, W), (3) evaluating individual compound variants for MLL1 inhibition, and (4) optimizing the most promising candidates. This segmented approach to molecular design and screening reduces overall development complexity while maintaining the goal of achieving selective MLL1 inhibition.
Data Source
AI summary
The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by mixed lineage leukemia 1 (MLL1).